<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Soluble membrane fractions derived from Raji cells trigger lymphocytes of Epstein-Barr virus (EBV)-seropositive, but not EBV-seronegative, individuals to release a lymphokine that inhibits leukocyte migration </plain></SENT>
<SENT sid="1" pm="."><plain>The reaction can be blocked by the sera of patients with EBV-DNA-carrying <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, or nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Absorption of these sera with EBV-positive, but not EBV-negative, cells abrogates their blocking activity </plain></SENT>
<SENT sid="3" pm="."><plain>These findings suggest that the antigen responsible for the leukocyte migration inhibition reaction is an EBV-encoded or an EBV-induced membrane component </plain></SENT>
<SENT sid="4" pm="."><plain>The antigen is not identical with EBV-associated nuclear antigen or any other known antibody-detected EBV antigen </plain></SENT>
</text></document>